XML 81 R70.htm IDEA: XBRL DOCUMENT v3.5.0.2
SHAREHOLDERS' EQUITY - Schedule of Shareholders' Equity (Details) - USD ($)
$ in Millions
3 Months Ended 9 Months Ended
Jun. 10, 2016
Mar. 27, 2015
Sep. 30, 2016
Sep. 30, 2015
Sep. 30, 2016
Sep. 30, 2015
Dec. 31, 2015
Increase (Decrease) in Shareholders' Equity              
Beginning Balance (in shares)         342,926,531    
Beginning Balance         $ 6,029.8 $ 5,401.7  
Effect of retrospective application of a new accounting standard (see Note 3)             $ 30.0
Issuance of common stock (in shares) 213,610 7,286,432          
Issuance of common stock   $ 1,450.0       1,481.0  
Common shares issued under share-based compensation plans         33.1 29.1  
Repurchases of common shares           (50.0)  
Share-based compensation         134.0 111.4  
Employee withholding taxes related to share-based awards         (9.1) (85.8)  
Excess tax benefits from share-based compensation           21.7  
Noncontrolling interest from business combinations           4.9  
Noncontrolling interest distributions         (9.1) (7.0)  
Total before comprehensive income (loss)     $ 6,208.7 $ 6,907.0 6,208.7 6,907.0  
Comprehensive loss:              
Net (loss) income     (1,219.1) 51.7 (1,896.0) 98.6  
Other comprehensive loss     (5.4) (173.7) (39.1) (549.7)  
Comprehensive loss     $ (1,224.5) (122.0) $ (1,935.1) (451.1)  
Ending Balance (in shares)     347,669,423   347,669,423    
Ending Balance     $ 4,273.6 6,455.9 $ 4,273.6 6,455.9  
Valeant Pharmaceuticals International, Inc. Shareholders’ Equity              
Increase (Decrease) in Shareholders' Equity              
Beginning Balance         5,911.0 5,279.4  
Effect of retrospective application of a new accounting standard (see Note 3)             30.0
Issuance of common stock           1,481.0  
Common shares issued under share-based compensation plans         33.1 29.1  
Repurchases of common shares           (50.0)  
Share-based compensation         134.0 111.4  
Employee withholding taxes related to share-based awards         (9.1) (85.8)  
Excess tax benefits from share-based compensation           21.7  
Total before comprehensive income (loss)     6,099.0 6,786.8 6,099.0 6,786.8  
Comprehensive loss:              
Net (loss) income         (1,894.4) 94.2  
Other comprehensive loss         (37.3) (547.5)  
Comprehensive loss         (1,931.7) (453.3)  
Ending Balance     $ 4,167.3 $ 6,333.5 $ 4,167.3 $ 6,333.5  
Common Shares              
Increase (Decrease) in Shareholders' Equity              
Beginning Balance (in shares)         342,900,000 334,400,000  
Beginning Balance         $ 9,897.4 $ 8,349.2  
Issuance of common stock (in shares)           7,500,000  
Issuance of common stock           $ 1,481.0  
Common shares issued under share-based compensation plans (in shares)         4,800,000 1,400,000  
Common shares issued under share-based compensation plans         $ 137.0 $ 75.7  
Repurchase of commons shares (in shares)           (200,000)  
Repurchases of common shares           $ (6.3)  
Total before comprehensive income (loss) (in shares)     347,700,000 343,100,000 347,700,000 343,100,000  
Total before comprehensive income (loss)     $ 10,034.4 $ 9,899.6 $ 10,034.4 $ 9,899.6  
Comprehensive loss:              
Ending Balance (in shares)     347,700,000 343,100,000 347,700,000 343,100,000  
Ending Balance     $ 10,034.4 $ 9,899.6 $ 10,034.4 $ 9,899.6  
Additional Paid-In Capital              
Increase (Decrease) in Shareholders' Equity              
Beginning Balance         304.9 243.9  
Common shares issued under share-based compensation plans         (103.9) (46.6)  
Share-based compensation         134.0 111.4  
Employee withholding taxes related to share-based awards         (9.1) (85.8)  
Excess tax benefits from share-based compensation           21.7  
Total before comprehensive income (loss)     325.9 244.6 325.9 244.6  
Comprehensive loss:              
Ending Balance     325.9 244.6 325.9 244.6  
Accumulated Deficit              
Increase (Decrease) in Shareholders' Equity              
Beginning Balance         (2,749.7) (2,397.8)  
Effect of retrospective application of a new accounting standard (see Note 3)             $ 30.0
Repurchases of common shares           (43.7)  
Total before comprehensive income (loss)     (2,719.7) (2,441.5) (2,719.7) (2,441.5)  
Comprehensive loss:              
Net (loss) income         (1,894.4) 94.2  
Ending Balance     (4,614.1) (2,347.3) (4,614.1) (2,347.3)  
Accumulated Other Comprehensive Loss              
Increase (Decrease) in Shareholders' Equity              
Beginning Balance         (1,541.6) (915.9)  
Total before comprehensive income (loss)     (1,541.6) (915.9) (1,541.6) (915.9)  
Comprehensive loss:              
Other comprehensive loss         (37.3) (547.5)  
Ending Balance     (1,578.9) (1,463.4) (1,578.9) (1,463.4)  
Noncontrolling Interest              
Increase (Decrease) in Shareholders' Equity              
Beginning Balance         118.8 122.3  
Noncontrolling interest from business combinations           4.9  
Noncontrolling interest distributions         (9.1) (7.0)  
Total before comprehensive income (loss)     109.7 120.2 109.7 120.2  
Comprehensive loss:              
Net (loss) income         (1.6) 4.4  
Other comprehensive loss         (1.8) (2.2)  
Comprehensive loss         (3.4) 2.2  
Ending Balance     $ 106.3 $ 122.4 $ 106.3 $ 122.4